We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Prestige Consumer Healthcare (PBH) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
The upcoming report from Prestige Consumer Healthcare (PBH - Free Report) is expected to reveal quarterly earnings of $1.09 per share, indicating an increase of 1.9% compared to the year-ago period. Analysts forecast revenues of $281.88 million, representing a decrease of 1.6% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Prestige Consumer Healthcare metrics that are commonly monitored and projected by Wall Street analysts.
Analysts predict that the 'Revenues- OTC Healthcare- International' will reach $42.94 million. The estimate suggests a change of +2.5% year over year.
The consensus among analysts is that 'Revenues- OTC Healthcare- North American' will reach $238.91 million. The estimate points to a change of -2.3% from the year-ago quarter.
According to the collective judgment of analysts, 'Gross profit- OTC Healthcare- North American' should come in at $133.75 million. The estimate compares to the year-ago value of $136.96 million.
The consensus estimate for 'Gross profit- OTC Healthcare- International' stands at $24.31 million. The estimate compares to the year-ago value of $23.06 million.
Prestige Consumer Healthcare shares have witnessed a change of +9.8% in the past month, in contrast to the Zacks S&P 500 composite's +0.7% move. With a Zacks Rank #3 (Hold), PBH is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Prestige Consumer Healthcare (PBH) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
The upcoming report from Prestige Consumer Healthcare (PBH - Free Report) is expected to reveal quarterly earnings of $1.09 per share, indicating an increase of 1.9% compared to the year-ago period. Analysts forecast revenues of $281.88 million, representing a decrease of 1.6% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Prestige Consumer Healthcare metrics that are commonly monitored and projected by Wall Street analysts.
Analysts predict that the 'Revenues- OTC Healthcare- International' will reach $42.94 million. The estimate suggests a change of +2.5% year over year.
The consensus among analysts is that 'Revenues- OTC Healthcare- North American' will reach $238.91 million. The estimate points to a change of -2.3% from the year-ago quarter.
According to the collective judgment of analysts, 'Gross profit- OTC Healthcare- North American' should come in at $133.75 million. The estimate compares to the year-ago value of $136.96 million.
The consensus estimate for 'Gross profit- OTC Healthcare- International' stands at $24.31 million. The estimate compares to the year-ago value of $23.06 million.
View all Key Company Metrics for Prestige Consumer Healthcare here>>>
Prestige Consumer Healthcare shares have witnessed a change of +9.8% in the past month, in contrast to the Zacks S&P 500 composite's +0.7% move. With a Zacks Rank #3 (Hold), PBH is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>